Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.2749
-0.0144-4.98%
Post-market: 0.27510.0002+0.07%18:45 EDT
Volume:1.41M
Turnover:394.93K
Market Cap:5.20M
PE:-0.07
High:0.2870
Open:0.2800
Low:0.2749
Close:0.2893
52wk High:14.80
52wk Low:0.2749
Shares:18.90M
Float Shares:17.23M
Volume Ratio:0.82
T/O Rate:8.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.16
PE(LYR):-0.06

Loading ...

VolitionRx Prepays in Full USD 7.5 Million Senior Secured Convertible Note Due 2027

Reuters
·
Sep 14

VolitionRX Limited Announces Pre-Payment in Full of $7.5 Million Senior Secured Convertible Promissory Note Due May 20, 2027

THOMSON REUTERS
·
Sep 14

VolitionRx Presents Early Stage I Solid Cancer Detection Data for Capture-Seq at ESMO MAP Conference

Reuters
·
Sep 10

VolitionRx Posts Corporate Deck Presentation on Nu.Q Diagnostics Strategy

Reuters
·
Sep 10

VolitionRx Highlights $5 Million Feline Paper Milestone in Corporate Deck

Reuters
·
Sep 10

VolitionRx Secures Lender Waiver for Above-Cap ATM Equity Sales Under Convertible Debt Deal

Reuters
·
Sep 03

VolitionRx Issues 4,698,628 Shares to Lind Global on Note Conversions Under Private Placement Exemption

Reuters
·
Sep 02

VolitionRx Files for Secondary Offering of Common Shares

MT Newswires Live
·
Aug 29

VolitionRX -Files Preliminary Prospectus for 10,006,360 Shares of Common Stock Offered by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Aug 29

VolitionRx Collaborates with Sysmex to Transfer Nu.Q NETs Assay Onto Sysmex Platform

Reuters
·
Aug 26

Press Release: VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

Dow Jones
·
Aug 26

VolitionRx Study Validates Nu.Q NETs H3.1 Biomarker as Predictor of 28-Day Sepsis Mortality, RRT Need

Reuters
·
Aug 26

VolitionRx Issues 773,361 Shares to Lind Global in Unregistered Note Conversions

Reuters
·
Aug 25

VolitionRX (VNRX) Receives a Buy from Maxim Group

TIPRANKS
·
Aug 18

VolitionRx Posts Corporate Deck Outlining Licensing-Led Strategy for Nu.Q Diagnostics in Cancer, Sepsis, Veterinary Testing

Reuters
·
Aug 14

VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate

Benzinga Earnings
·
Aug 14

VolitionRx Q2 FY26 Operating Loss Narrows 34% to $4.2 Million; Operating Expenses Fall 32% on Year

Reuters
·
Aug 14

VolitionRX Limited Announces Second Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
Aug 14

VolitionRx Says Finger-Prick Sepsis Test Tracks Lab Nu.Q NETs Assay in Clinical Study

Reuters
·
Aug 12

VolitionRx Gelar Konferensi Kinerja Kuartal II 2026 Dan Pembaruan Bisnis

Reuters
·
Aug 12